1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Acute Kidney Injury - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2024-2034)
4.4 Market Overview (2019-2024) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Acute Kidney Injury - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Acute Kidney Injury - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Acute Kidney Injury - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Acute Kidney Injury - Unmet Needs
10 Acute Kidney Injury - Key Endpoints of Treatment
11 Acute Kidney Injury - Marketed Products
11.1 List of Acute Kidney Injury Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Acute Kidney Injury - Pipeline Drugs
12.1 List of Acute Kidney Injury Pipeline Drugs Across the Top 7 Markets
12.1.1 SBI 101 - Sentien Biotechnologies
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TIN816 - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 RMC 035 - Guard Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 RBT-1 - Renibus Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 OCE 205 - Ocelot Bio
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Acute Kidney Injury - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Acute Kidney Injury – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Acute Kidney Injury - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Kidney Injury - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Kidney Injury - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Kidney Injury - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Kidney Injury - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Kidney Injury - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Kidney Injury - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Kidney Injury - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Kidney Injury - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Kidney Injury - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Kidney Injury - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Kidney Injury - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Kidney Injury - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Kidney Injury - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Kidney Injury - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Kidney Injury - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Kidney Injury - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Kidney Injury - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Kidney Injury - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Kidney Injury - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Kidney Injury - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Kidney Injury - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Kidney Injury - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Kidney Injury - Access and Reimbursement Overview
16 Acute Kidney Injury - Recent Events and Inputs From Key Opinion Leaders
17 Acute Kidney Injury Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Acute Kidney Injury Market – Strategic Recommendations
19 Appendix